Status:
COMPLETED
GALNT4 in Patients With Acute Coronary Syndrome
Lead Sponsor:
The First Affiliated Hospital of Dalian Medical University
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-80 years
Brief Summary
The expression of GALNT4 in blood with acute coronary syndrome
Detailed Description
Emerging evidences have linked GALNTs to cardiovascular disease or susceptibility to CAD.GALNT4, a member of the GalNAc-Ts family,contributes to the initiation of O-linked. Polymorphisms in GALNT4 hav...
Eligibility Criteria
Inclusion
- diagnosed as acute coronary syndrome,including STEMI,NSTE-ACS,or diagnosed as SAP by CAG.
- with left ventricular ejection fraction（LVEF）\>=45%
- written informed consents are obtained
- admitted within 24 hours after chest pain attacked(except SAP)
Exclusion
- • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy
- complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction
- with acute or chronic infection, surgery or trauma in the last month
- secondary hypertension, severe liver dysfunction,severe renal insufficiency
- with abnormal thyroid function or allergy to iodine agent
- refusal to sign the informed consent
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03335514
Start Date
September 1 2017
End Date
December 31 2018
Last Update
March 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China, 116011